Curatis Holding AG (CHIX:CURNZ) EBITDA Margin % : -171.91% (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Curatis Holding AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Curatis Holding AG's EBITDA for the six months ended in Jun. 2024 was CHF-3.40 Mil. Curatis Holding AG's Revenue for the six months ended in Jun. 2024 was CHF1.98 Mil. Therefore, Curatis Holding AG's EBITDA margin for the quarter that ended in Jun. 2024 was -171.91%.

Curatis Holding AG EBITDA Margin % Historical Data

The historical data trend for Curatis Holding AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG EBITDA Margin % Chart

Curatis Holding AG Annual Data

Trend

Dec21

Dec22

Dec23

EBITDA Margin %

Curatis Holding AG Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBITDA Margin %	Get a 7-Day Free Trial			-	-	-	-	-171.91

Competitive Comparison of Curatis Holding AG's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curatis Holding AG's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Curatis Holding AG's EBITDA Margin % falls into.

Curatis Holding AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Curatis Holding AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-50.26	/	0
	=	%

Curatis Holding AG's EBITDA Margin % for the quarter that ended in Jun. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-3.402	/	1.979
	=	-171.91 %

Curatis Holding AG (CHIX:CURNz) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Curatis Holding AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Curatis Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (CHIX:CURNz) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

0QNS:UK CURN:Switzerland

Address

Weierweg 7, Liestal, CHE, CH-4410

Website

https://www.curatis.com

Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.

Curatis Holding AG Headlines

No Headlines